ReviewFrontiers in medicine2021
Recent Progress in Lyme Disease and Remaining Challenges.
Review in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 2 syntheses or guidelines pooled it, 148 citations in OpenAlex.
- Incidence of Lyme Borreliosis in Europe from National Surveillance Systems (2005-2020).Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2023Pooled it
- Seroprevalence of Lyme Borreliosis in Europe: Results from a Systematic Literature Review (2005-2020).Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2023Pooled it
- A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals.Nature communications · 2026Trial
- Borrelia burgdorferi disrupts gut barrier functions and microbiota-antibody interactions.The Journal of experimental medicine · 2026Article
- The ecology of Lyme disease: Long-term data, surprises, and a synthesis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Post-Treatment Lyme Disease Syndrome in Six European Countries Using Data from the Burden of Lyme Disease (BOLD) Study.Pathogens (Basel, Switzerland) · 2026Article
- Protective efficacy of mutant strains ofInfection and immunity · 2026Article
- Article
- Borrelia burgdorferi sensu lato Employs Several Escape Mechanisms to Bypass the Human Defense System.European journal of immunology · 2026Review
- Efficacy of Purified Borrelial Lipoproteins (PBL) as an oral formulation in reducing transmission of Lyme spirochetes from reservoir hosts tobioRxiv : the preprint server for biology · 2026Article
- Characterization ofMicroorganisms · 2026Article
- Assessment of lipid mediators in the urine of patients with Lyme disease, tick-borne encephalitis and human granulocytic anaplasmosis.Scientific reports · 2026Article
- Pilot study of psilocybin in patients with post-treatment lyme disease.Scientific reports · 2026Article
- Ecological and Epidemiological Consequences of Tick-Control Interventions in Residential Neighborhoods: A Synthesis of The Tick Project.Transboundary and emerging diseases · 2026Review
- Peptidoglycan architecture dictates protein interactions, tissue tropism, and arthritis in the Lyme disease spirochete Borrelia burgdorferi.PLoS pathogens · 2026Article
- Polyvalent mRNA vaccine targeting outer surface protein C affords multi-strain protection against Lyme disease.NPJ vaccines · 2025Article
- Lyme Disease Incidence in Massachusetts, 2012-2024.JAMA network open · 2025Article
- Harnessing 50 years of tick population genetics: Choosing the right molecular tool for contemporary research.The Journal of animal ecology · 2025Review
- Lyme Borreliosis Incidence Across Europe, 2015-2023: A Surveillance-Based Review and Analysis.Vector borne and zoonotic diseases (Larchmont, N.Y.) · 2025Review
- Audio-Vestibular Function in Patients Diagnosed with Lyme Neuroborreliosis.The journal of international advanced otology · 2025Article
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 18 institutions in 2 countries.
Funding
Abstract
Lyme disease (also known as Lyme borreliosis) is the most common vector-borne disease in the United States with an estimated 476,000 cases per year. While historically, the long-term impact of Lyme disease on patients has been controversial, mounting evidence supports the idea that a substantial number of patients experience persistent symptoms following treatment. The research community has largely lacked the necessary funding to properly advance the scientific and clinical understanding of the disease, or to develop and evaluate innovative approaches for prevention, diagnosis, and treatment. Given the many outstanding questions raised into the diagnosis, clinical presentation and treatment of Lyme disease, and the underlying molecular mechanisms that trigger persistent disease, there is an urgent need for more support. This review article summarizes progress over the past 5 years in our understanding of Lyme and tick-borne diseases in the United States and highlights remaining challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.